KR20090023698A - 2-아닐리노-4-아미노알킬렌아미노피리미딘 - Google Patents
2-아닐리노-4-아미노알킬렌아미노피리미딘 Download PDFInfo
- Publication number
- KR20090023698A KR20090023698A KR1020097000880A KR20097000880A KR20090023698A KR 20090023698 A KR20090023698 A KR 20090023698A KR 1020097000880 A KR1020097000880 A KR 1020097000880A KR 20097000880 A KR20097000880 A KR 20097000880A KR 20090023698 A KR20090023698 A KR 20090023698A
- Authority
- KR
- South Korea
- Prior art keywords
- pyrimidine
- diamine
- dimethylamino
- propyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 102100024924 Protein kinase C alpha type Human genes 0.000 claims abstract description 42
- 206010019280 Heart failures Diseases 0.000 claims abstract description 37
- 239000003112 inhibitor Substances 0.000 claims abstract description 31
- 101710109947 Protein kinase C alpha type Proteins 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000002107 myocardial effect Effects 0.000 claims abstract description 9
- -1 tert-butyl Compound Chemical class 0.000 claims description 251
- 150000001875 compounds Chemical class 0.000 claims description 80
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 8
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- OUWFKBADUBMKCE-UHFFFAOYSA-N ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCCCN(C)C)N Chemical compound ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCCCN(C)C)N OUWFKBADUBMKCE-UHFFFAOYSA-N 0.000 claims description 7
- OETDDGSVFVKYNJ-UHFFFAOYSA-N ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCCN(C)C)N Chemical compound ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCCN(C)C)N OETDDGSVFVKYNJ-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
- 206010003119 arrhythmia Diseases 0.000 claims description 5
- 230000006793 arrhythmia Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002478 aldosterone Drugs 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 3
- 108020001621 Natriuretic Peptide Proteins 0.000 claims description 3
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 229960005156 digoxin Drugs 0.000 claims description 3
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 3
- 230000010247 heart contraction Effects 0.000 claims description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 239000000692 natriuretic peptide Substances 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 3
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 claims description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- ODMBGNJCHPHHDF-UHFFFAOYSA-N 2-N-(2,3-dichlorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C(=CC=C1)Cl)Cl)N)C ODMBGNJCHPHHDF-UHFFFAOYSA-N 0.000 claims description 2
- GPJDECPRTPFECU-UHFFFAOYSA-N 2-N-(2,3-difluorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C(=CC=C1)F)F)N)C GPJDECPRTPFECU-UHFFFAOYSA-N 0.000 claims description 2
- PVEGPJMMTIABDL-UHFFFAOYSA-N 2-N-(2,4-dichlorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=C(C=C1)Cl)Cl)N)C PVEGPJMMTIABDL-UHFFFAOYSA-N 0.000 claims description 2
- WHENPRWNUPATTR-UHFFFAOYSA-N 2-N-(2,4-difluorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=C(C=C1)F)F)N)C WHENPRWNUPATTR-UHFFFAOYSA-N 0.000 claims description 2
- TVUNOPICWVAYRM-UHFFFAOYSA-N 2-N-(2,5-dichlorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=CC(=C1)Cl)Cl)N)C TVUNOPICWVAYRM-UHFFFAOYSA-N 0.000 claims description 2
- RGZLGNGWPUMWSS-UHFFFAOYSA-N 2-N-(2,5-difluorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=CC(=C1)F)F)N)C RGZLGNGWPUMWSS-UHFFFAOYSA-N 0.000 claims description 2
- LSJYBUXEXWYIBZ-UHFFFAOYSA-N 2-N-(2,6-dichlorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=CC=C1Cl)Cl)N)C LSJYBUXEXWYIBZ-UHFFFAOYSA-N 0.000 claims description 2
- QLVMYWVNEMSXAW-UHFFFAOYSA-N 2-N-(2,6-difluorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=CC=C1F)F)N)C QLVMYWVNEMSXAW-UHFFFAOYSA-N 0.000 claims description 2
- VJUMCESHJIUABG-UHFFFAOYSA-N 2-N-(2-chlorophenyl)-4-[3-(dimethylamino)propyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=CC=C1)Cl)N)C VJUMCESHJIUABG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 2
- GEFNYYRTOIVPIV-UHFFFAOYSA-N 4-(3-aminopropyl)-2-N-(3-chlorophenyl)-1H-pyrimidine-2,4-diamine Chemical compound NCCCC1(NC(=NC=C1)NC1=CC(=CC=C1)Cl)N GEFNYYRTOIVPIV-UHFFFAOYSA-N 0.000 claims description 2
- UJKFLVPHOMCNRS-UHFFFAOYSA-N 4-(3-aminopropyl)-2-N-(3-chlorophenyl)-4-N-methyl-1H-pyrimidine-2,4-diamine Chemical compound NCCCC1(NC(=NC=C1)NC1=CC(=CC=C1)Cl)NC UJKFLVPHOMCNRS-UHFFFAOYSA-N 0.000 claims description 2
- JBHPOUDVFPSNJF-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(2,3-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C(=CC=C1)C)C)N)C JBHPOUDVFPSNJF-UHFFFAOYSA-N 0.000 claims description 2
- JHCKEJSPMLLCAD-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(2,4-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=C(C=C1)C)C)N)C JHCKEJSPMLLCAD-UHFFFAOYSA-N 0.000 claims description 2
- JRRNKTTXSRQGNU-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(2,5-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=CC(=C1)C)C)N)C JRRNKTTXSRQGNU-UHFFFAOYSA-N 0.000 claims description 2
- BJGJJEOTKJPUGV-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(2,6-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=CC=C1C)C)N)C BJGJJEOTKJPUGV-UHFFFAOYSA-N 0.000 claims description 2
- MZVYYQASXZRZIQ-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(2-methylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=C(C=CC=C1)C)N)C MZVYYQASXZRZIQ-UHFFFAOYSA-N 0.000 claims description 2
- KLHCEMXXYCSLBQ-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(3,4-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=CC(=C(C=C1)C)C)N)C KLHCEMXXYCSLBQ-UHFFFAOYSA-N 0.000 claims description 2
- MSQRDWKOIHEDCI-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(3-ethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=CC(=CC=C1)CC)N)C MSQRDWKOIHEDCI-UHFFFAOYSA-N 0.000 claims description 2
- ABYOBAIETXYKJA-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(3-fluorophenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=CC(=CC=C1)F)N)C ABYOBAIETXYKJA-UHFFFAOYSA-N 0.000 claims description 2
- NHHRCPJSHYDRLE-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(4-fluorophenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=CC=C(C=C1)F)N)C NHHRCPJSHYDRLE-UHFFFAOYSA-N 0.000 claims description 2
- BXQRKCYZZNEBDX-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(4-methylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=CC=C(C=C1)C)N)C BXQRKCYZZNEBDX-UHFFFAOYSA-N 0.000 claims description 2
- JKLTWFPCPVVFDW-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-[3-(trifluoromethyl)phenyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=CC(=CC=C1)C(F)(F)F)N)C JKLTWFPCPVVFDW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- NGOHDHNOSJSVFL-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C1(NC=CC(=N1)NCCCN(C)C)N)C(F)(F)F Chemical compound ClC1=C(C=C(C=C1)C1(NC=CC(=N1)NCCCN(C)C)N)C(F)(F)F NGOHDHNOSJSVFL-UHFFFAOYSA-N 0.000 claims description 2
- HOAZEVKPSVSLAT-UHFFFAOYSA-N ClC=1C=C(C=CC1F)C1(NC=CC(=N1)NCCCN(C)C)N Chemical compound ClC=1C=C(C=CC1F)C1(NC=CC(=N1)NCCCN(C)C)N HOAZEVKPSVSLAT-UHFFFAOYSA-N 0.000 claims description 2
- MZIWWHRFHREZBD-UHFFFAOYSA-N ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCCN(CC)CC)N Chemical compound ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCCN(CC)CC)N MZIWWHRFHREZBD-UHFFFAOYSA-N 0.000 claims description 2
- ZENUXLIRRCIMBN-UHFFFAOYSA-N ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCCNC)N Chemical compound ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCCNC)N ZENUXLIRRCIMBN-UHFFFAOYSA-N 0.000 claims description 2
- KXTQXQAIEWUDJS-UHFFFAOYSA-N ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCN(C)C)N Chemical compound ClC=1C=C(C=CC=1)C1(NC=CC(=N1)NCCN(C)C)N KXTQXQAIEWUDJS-UHFFFAOYSA-N 0.000 claims description 2
- UIHFEIOFJNNYQK-UHFFFAOYSA-N ClC=1C=C(C=CC=1C)C1(NC=CC(=N1)NCCCN(C)C)N Chemical compound ClC=1C=C(C=CC=1C)C1(NC=CC(=N1)NCCCN(C)C)N UIHFEIOFJNNYQK-UHFFFAOYSA-N 0.000 claims description 2
- IPDYZQFTHMIFKF-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)C1(NC=CC(=N1)NCCCN(C)C)N Chemical compound ClC=1C=C(C=CC=1Cl)C1(NC=CC(=N1)NCCCN(C)C)N IPDYZQFTHMIFKF-UHFFFAOYSA-N 0.000 claims description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 2
- KZHKAUVIAXFFQY-UHFFFAOYSA-N FC=1C=C(C=CC=1F)C1(NC=CC(=N1)NCCCN(C)C)N Chemical compound FC=1C=C(C=CC=1F)C1(NC=CC(=N1)NCCCN(C)C)N KZHKAUVIAXFFQY-UHFFFAOYSA-N 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010042434 Sudden death Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 230000008694 endothelial dysfunction Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000004041 inotropic agent Substances 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 230000011278 mitosis Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000003087 receptor blocking agent Substances 0.000 claims description 2
- 230000036454 renin-angiotensin system Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims 4
- OCNQDKJOGFPUSW-UHFFFAOYSA-N ClC=1C=C(C=CC1)C1(NC=CC(=N1)NCCC(C)N(C)C)N Chemical compound ClC=1C=C(C=CC1)C1(NC=CC(=N1)NCCC(C)N(C)C)N OCNQDKJOGFPUSW-UHFFFAOYSA-N 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004825 2,2-dimethylpropylene group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[*:1])C([H])([H])[*:2] 0.000 claims 1
- MLSXPHPBGMFHSW-UHFFFAOYSA-N 4-[3-(dimethylamino)-2,2-dimethylpropyl]-2-N-[3-(trifluoromethyl)phenyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CC(CC1(NC(=NC=C1)NC1=CC(=CC=C1)C(F)(F)F)N)(C)C)C MLSXPHPBGMFHSW-UHFFFAOYSA-N 0.000 claims 1
- OGZSZGHVSMRPEZ-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-2-N-(3-methylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCC1(NC(=NC=C1)NC1=CC(=CC=C1)C)N)C OGZSZGHVSMRPEZ-UHFFFAOYSA-N 0.000 claims 1
- ZSXCBJQKIMDPOM-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)C)C)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)C)C)N)C)C ZSXCBJQKIMDPOM-UHFFFAOYSA-N 0.000 claims 1
- OCRIZLNRYRNTEF-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)Cl)Cl)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)Cl)Cl)N)C)C OCRIZLNRYRNTEF-UHFFFAOYSA-N 0.000 claims 1
- UXEFXBDTYKHIQK-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)F)F)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)F)F)N)C)C UXEFXBDTYKHIQK-UHFFFAOYSA-N 0.000 claims 1
- PCCPBMNHLMSOPO-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=C(C=C1)C)C)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=C(C=C1)C)C)N)C)C PCCPBMNHLMSOPO-UHFFFAOYSA-N 0.000 claims 1
- NGVBFOKIMNVABU-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=C(C=C1)F)F)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=C(C=C1)F)F)N)C)C NGVBFOKIMNVABU-UHFFFAOYSA-N 0.000 claims 1
- SKZRZCQQMVDJDU-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)C)C)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)C)C)N)C)C SKZRZCQQMVDJDU-UHFFFAOYSA-N 0.000 claims 1
- PMVQSUGJNZSKQG-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)Cl)Cl)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)Cl)Cl)N)C)C PMVQSUGJNZSKQG-UHFFFAOYSA-N 0.000 claims 1
- SJBMZFRMGNXLML-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)F)F)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)F)F)N)C)C SJBMZFRMGNXLML-UHFFFAOYSA-N 0.000 claims 1
- GBRHPGLWPZCYRD-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1)C)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1)C)N)C)C GBRHPGLWPZCYRD-UHFFFAOYSA-N 0.000 claims 1
- AKPNFDGGBNFAJW-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1)Cl)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1)Cl)N)C)C AKPNFDGGBNFAJW-UHFFFAOYSA-N 0.000 claims 1
- YVIFJCLGJXQRQF-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1C)C)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1C)C)N)C)C YVIFJCLGJXQRQF-UHFFFAOYSA-N 0.000 claims 1
- AQTLQWHRWIJEHL-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1Cl)Cl)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1Cl)Cl)N)C)C AQTLQWHRWIJEHL-UHFFFAOYSA-N 0.000 claims 1
- RDLAYHFSXNBWNZ-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1F)F)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=C(C=CC=C1F)F)N)C)C RDLAYHFSXNBWNZ-UHFFFAOYSA-N 0.000 claims 1
- XAHXUNOJDFBGSR-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=CC(=CC=C1)F)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=CC(=CC=C1)F)N)C)C XAHXUNOJDFBGSR-UHFFFAOYSA-N 0.000 claims 1
- FUGXISJGCDABPJ-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=CC=C(C=C1)C)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=CC=C(C=C1)C)N)C)C FUGXISJGCDABPJ-UHFFFAOYSA-N 0.000 claims 1
- ZCLVQIIOIMBZGU-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=CC=C(C=C1)Cl)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=CC=C(C=C1)Cl)N)C)C ZCLVQIIOIMBZGU-UHFFFAOYSA-N 0.000 claims 1
- PJCBMUAVFOBSAN-UHFFFAOYSA-N CN(C(CCC1(NC(=NC=C1)NC1=CC=C(C=C1)F)N)C)C Chemical compound CN(C(CCC1(NC(=NC=C1)NC1=CC=C(C=C1)F)N)C)C PJCBMUAVFOBSAN-UHFFFAOYSA-N 0.000 claims 1
- ZLHZXTSXXCEHCY-UHFFFAOYSA-N CN(CCCC1(NC(=NC=C1)NC1=CC(=CC=C1)OC)N)C Chemical compound CN(CCCC1(NC(=NC=C1)NC1=CC(=CC=C1)OC)N)C ZLHZXTSXXCEHCY-UHFFFAOYSA-N 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 229940097420 Diuretic Drugs 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000011575 calcium Substances 0.000 abstract description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 10
- 229910052791 calcium Inorganic materials 0.000 abstract description 10
- 125000006294 amino alkylene group Chemical group 0.000 abstract description 8
- 150000005005 aminopyrimidines Chemical class 0.000 abstract description 8
- 230000008602 contraction Effects 0.000 abstract description 7
- 230000003834 intracellular effect Effects 0.000 abstract description 6
- 108010050276 Protein Kinase C-alpha Proteins 0.000 abstract description 5
- 210000004413 cardiac myocyte Anatomy 0.000 abstract description 5
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 230000000116 mitigating effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000010992 reflux Methods 0.000 description 31
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 19
- 150000001768 cations Chemical class 0.000 description 19
- 230000000670 limiting effect Effects 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 108090000315 Protein Kinase C Proteins 0.000 description 11
- 102000003923 Protein Kinase C Human genes 0.000 description 11
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 10
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 9
- UYHSQVMHSFXUOA-UHFFFAOYSA-N 2-methylthiouracil Chemical compound CSC1=NC=CC(O)=N1 UYHSQVMHSFXUOA-UHFFFAOYSA-N 0.000 description 9
- VRKQTFNBURPJHT-UHFFFAOYSA-N 4-chloro-n-[3-(trifluoromethyl)phenyl]pyrimidin-2-amine Chemical compound FC(F)(F)C1=CC=CC(NC=2N=C(Cl)C=CN=2)=C1 VRKQTFNBURPJHT-UHFFFAOYSA-N 0.000 description 9
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 208000010125 myocardial infarction Diseases 0.000 description 9
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 230000000004 hemodynamic effect Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- YBOHNQNCXZWDSL-UHFFFAOYSA-N 2-(3-chloroanilino)-1h-pyrimidin-6-one Chemical compound ClC1=CC=CC(NC=2NC(=O)C=CN=2)=C1 YBOHNQNCXZWDSL-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 150000001982 diacylglycerols Chemical class 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
- CPEJAAQYFUKMBX-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-1h-pyrimidin-6-one Chemical compound FC(F)(F)C1=CC=CC(NC=2NC(=O)C=CN=2)=C1 CPEJAAQYFUKMBX-UHFFFAOYSA-N 0.000 description 4
- CJBHZQJLFPOTCN-UHFFFAOYSA-N 4-chloro-n-(3-chlorophenyl)pyrimidin-2-amine Chemical compound ClC1=CC=CC(NC=2N=C(Cl)C=CN=2)=C1 CJBHZQJLFPOTCN-UHFFFAOYSA-N 0.000 description 4
- HEIWTBPTJKTITB-UHFFFAOYSA-N 4-chloro-n-[3-(2-methyl-1,3-thiazol-4-yl)phenyl]pyrimidin-2-amine Chemical compound S1C(C)=NC(C=2C=C(NC=3N=C(Cl)C=CN=3)C=CC=2)=C1 HEIWTBPTJKTITB-UHFFFAOYSA-N 0.000 description 4
- FYTQYXZPZGJHFF-UHFFFAOYSA-N 4-n-[3-(dimethylamino)-2,2-dimethylpropyl]-2-n-[3-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine;hydrochloride Chemical compound Cl.CN(C)CC(C)(C)CNC1=CC=NC(NC=2C=C(C=CC=2)C(F)(F)F)=N1 FYTQYXZPZGJHFF-UHFFFAOYSA-N 0.000 description 4
- BCDDVQGIIPMNNK-UHFFFAOYSA-N 4-n-[3-(dimethylamino)propyl]-2-n-[3-(2-methyl-1,3-thiazol-4-yl)phenyl]pyrimidine-2,4-diamine;hydrochloride Chemical compound Cl.CN(C)CCCNC1=CC=NC(NC=2C=C(C=CC=2)C=2N=C(C)SC=2)=N1 BCDDVQGIIPMNNK-UHFFFAOYSA-N 0.000 description 4
- HAESGGVFLVCZQP-UHFFFAOYSA-N Cl.CN(C)CCCC1(N)NC(N)=NC=C1 Chemical compound Cl.CN(C)CCCC1(N)NC(N)=NC=C1 HAESGGVFLVCZQP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010044467 Isoenzymes Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- 125000004809 1-methylpropylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- VXNUVYNZKFXBGW-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(4-fluorophenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=CC=C(C=C1)F)N)C VXNUVYNZKFXBGW-UHFFFAOYSA-N 0.000 description 2
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 2
- 239000004254 Ammonium phosphate Substances 0.000 description 2
- 101710200897 Asialoglycoprotein receptor 1 Proteins 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 102100023353 Intelectin-1 Human genes 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000019269 advanced heart failure Diseases 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 description 2
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 2
- 235000019289 ammonium phosphates Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000002371 cardiac agent Substances 0.000 description 2
- 108010010352 cardiac glycoside receptors Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000000068 chlorophenyl group Chemical group 0.000 description 2
- 230000006690 co-activation Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- GCOWZPRIMFGIDQ-UHFFFAOYSA-N n',n'-dimethylbutane-1,4-diamine Chemical compound CN(C)CCCCN GCOWZPRIMFGIDQ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- AMLFJZRZIOZGPW-UHFFFAOYSA-N prop-1-en-1-amine Chemical group CC=CN AMLFJZRZIOZGPW-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- ZYGCUMLAHDLONP-UHFFFAOYSA-N 1-(2-oxopiperidin-3-yl)piperidin-2-one Chemical compound O=C1NCCCC1N1C(=O)CCCC1 ZYGCUMLAHDLONP-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
- QZQIZDMKVWJTFK-UHFFFAOYSA-N 2-N-(2,3-dichlorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)Cl)Cl)N)C QZQIZDMKVWJTFK-UHFFFAOYSA-N 0.000 description 1
- XFYZAPIZDPDFJQ-UHFFFAOYSA-N 2-N-(2,3-dichlorophenyl)-4-[4-(dimethylamino)butyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C(=CC=C1)Cl)Cl)N)C XFYZAPIZDPDFJQ-UHFFFAOYSA-N 0.000 description 1
- VCDUNWSVDFYAFV-UHFFFAOYSA-N 2-N-(2,3-difluorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)F)F)N)C VCDUNWSVDFYAFV-UHFFFAOYSA-N 0.000 description 1
- UHMHQJVFGIOICQ-UHFFFAOYSA-N 2-N-(2,4-dichlorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=C(C=C1)Cl)Cl)N)C UHMHQJVFGIOICQ-UHFFFAOYSA-N 0.000 description 1
- KUMBSBKIZNYQSS-UHFFFAOYSA-N 2-N-(2,4-dichlorophenyl)-4-[4-(dimethylamino)butyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C=C(C=C1)Cl)Cl)N)C KUMBSBKIZNYQSS-UHFFFAOYSA-N 0.000 description 1
- OHIHXERRMRNSGJ-UHFFFAOYSA-N 2-N-(2,4-difluorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=C(C=C1)F)F)N)C OHIHXERRMRNSGJ-UHFFFAOYSA-N 0.000 description 1
- ZYFNAZGUYXRESU-UHFFFAOYSA-N 2-N-(2,5-dichlorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)Cl)Cl)N)C ZYFNAZGUYXRESU-UHFFFAOYSA-N 0.000 description 1
- YUTBUJWUHTVSHO-UHFFFAOYSA-N 2-N-(2,5-dichlorophenyl)-4-[4-(dimethylamino)butyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C=CC(=C1)Cl)Cl)N)C YUTBUJWUHTVSHO-UHFFFAOYSA-N 0.000 description 1
- XNFFXJSFTRRSEM-UHFFFAOYSA-N 2-N-(2,5-difluorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)F)F)N)C XNFFXJSFTRRSEM-UHFFFAOYSA-N 0.000 description 1
- PPZGYIHSMASJBL-UHFFFAOYSA-N 2-N-(2,6-dichlorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=CC=C1Cl)Cl)N)C PPZGYIHSMASJBL-UHFFFAOYSA-N 0.000 description 1
- VKRHEZMFYCTVSI-UHFFFAOYSA-N 2-N-(2,6-dichlorophenyl)-4-[4-(dimethylamino)butyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C=CC=C1Cl)Cl)N)C VKRHEZMFYCTVSI-UHFFFAOYSA-N 0.000 description 1
- XROQYCWIEAPFPQ-UHFFFAOYSA-N 2-N-(2,6-difluorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=CC=C1F)F)N)C XROQYCWIEAPFPQ-UHFFFAOYSA-N 0.000 description 1
- HENHFSWLVBGWHY-UHFFFAOYSA-N 2-N-(2-chlorophenyl)-4-[2-(dimethylamino)ethyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=CC=C1)Cl)N)C HENHFSWLVBGWHY-UHFFFAOYSA-N 0.000 description 1
- PASYCLKHJYWYAN-UHFFFAOYSA-N 2-N-(2-chlorophenyl)-4-[4-(dimethylamino)butyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C=CC=C1)Cl)N)C PASYCLKHJYWYAN-UHFFFAOYSA-N 0.000 description 1
- XDDWVTRAEMZYDZ-UHFFFAOYSA-N 2-N-(4-chlorophenyl)-4-[4-(dimethylamino)butyl]-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=CC=C(C=C1)Cl)N)C XDDWVTRAEMZYDZ-UHFFFAOYSA-N 0.000 description 1
- CCFJYCNNNMNBQV-UHFFFAOYSA-N 2-[3-(2-methyl-1,3-thiazol-4-yl)anilino]-1h-pyrimidin-6-one Chemical compound S1C(C)=NC(C=2C=C(NC=3NC(=O)C=CN=3)C=CC=2)=C1 CCFJYCNNNMNBQV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004807 2-methylethylene group Chemical group [H]C([H])([H])C([H])([*:2])C([H])([H])[*:1] 0.000 description 1
- 125000004810 2-methylpropylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])[*:1] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- CPHZPWZSSBCSAH-UHFFFAOYSA-N 3-(2-methyl-1,3-thiazol-4-yl)aniline Chemical compound S1C(C)=NC(C=2C=C(N)C=CC=2)=C1 CPHZPWZSSBCSAH-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- 229940105325 3-dimethylaminopropylamine Drugs 0.000 description 1
- MUNOBADFTHUUFG-UHFFFAOYSA-N 3-phenylaniline Chemical group NC1=CC=CC(C=2C=CC=CC=2)=C1 MUNOBADFTHUUFG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OJNVRUPXNTWECT-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(2,3-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C(=CC=C1)C)C)N)C OJNVRUPXNTWECT-UHFFFAOYSA-N 0.000 description 1
- RDAVYCYGXAUBKS-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(2,4-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=C(C=C1)C)C)N)C RDAVYCYGXAUBKS-UHFFFAOYSA-N 0.000 description 1
- XCLWOVKFVWHTQO-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(2,5-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=CC(=C1)C)C)N)C XCLWOVKFVWHTQO-UHFFFAOYSA-N 0.000 description 1
- WHOYPCUONNNMJZ-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(2,6-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=CC=C1C)C)N)C WHOYPCUONNNMJZ-UHFFFAOYSA-N 0.000 description 1
- VCKGOSBVWWHVTB-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(2-methylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=C(C=CC=C1)C)N)C VCKGOSBVWWHVTB-UHFFFAOYSA-N 0.000 description 1
- MIWOZKOHPOYRAP-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(3,4-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=CC(=C(C=C1)C)C)N)C MIWOZKOHPOYRAP-UHFFFAOYSA-N 0.000 description 1
- VDGQGHMWGYXESR-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(3-fluorophenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=CC(=CC=C1)F)N)C VDGQGHMWGYXESR-UHFFFAOYSA-N 0.000 description 1
- GARYEVBMPJMKOX-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(3-methylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=CC(=CC=C1)C)N)C GARYEVBMPJMKOX-UHFFFAOYSA-N 0.000 description 1
- OTOPSGXVWUGKFF-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]-2-N-(4-methylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCC1(NC(=NC=C1)NC1=CC=C(C=C1)C)N)C OTOPSGXVWUGKFF-UHFFFAOYSA-N 0.000 description 1
- RLIRABVUWLXRQO-UHFFFAOYSA-N 4-[4-(dimethylamino)butyl]-2-N-(2,3-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C(=CC=C1)C)C)N)C RLIRABVUWLXRQO-UHFFFAOYSA-N 0.000 description 1
- KCRFQYURPQRAEA-UHFFFAOYSA-N 4-[4-(dimethylamino)butyl]-2-N-(2,4-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C=C(C=C1)C)C)N)C KCRFQYURPQRAEA-UHFFFAOYSA-N 0.000 description 1
- GKBUMTOTUFFNJC-UHFFFAOYSA-N 4-[4-(dimethylamino)butyl]-2-N-(2,5-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C=CC(=C1)C)C)N)C GKBUMTOTUFFNJC-UHFFFAOYSA-N 0.000 description 1
- HQUXOLIHQGRQOT-UHFFFAOYSA-N 4-[4-(dimethylamino)butyl]-2-N-(2,6-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C=CC=C1C)C)N)C HQUXOLIHQGRQOT-UHFFFAOYSA-N 0.000 description 1
- IGYDKABWUOZIPB-UHFFFAOYSA-N 4-[4-(dimethylamino)butyl]-2-N-(2-methylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=C(C=CC=C1)C)N)C IGYDKABWUOZIPB-UHFFFAOYSA-N 0.000 description 1
- MICVCQPFHNDVIO-UHFFFAOYSA-N 4-[4-(dimethylamino)butyl]-2-N-(3,4-dimethylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=CC(=C(C=C1)C)C)N)C MICVCQPFHNDVIO-UHFFFAOYSA-N 0.000 description 1
- UBIGGPGOYCJWIE-UHFFFAOYSA-N 4-[4-(dimethylamino)butyl]-2-N-(4-fluorophenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=CC=C(C=C1)F)N)C UBIGGPGOYCJWIE-UHFFFAOYSA-N 0.000 description 1
- ZNQQARWKDYHVRG-UHFFFAOYSA-N 4-[4-(dimethylamino)butyl]-2-N-(4-methylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CN(CCCCC1(NC(=NC=C1)NC1=CC=C(C=C1)C)N)C ZNQQARWKDYHVRG-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- BJUPTJXRJDXLHF-UHFFFAOYSA-N 6,7-dihydro-5h-cyclopenta[d]pyrimidine Chemical compound N1=CN=C2CCCC2=C1 BJUPTJXRJDXLHF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- VQZLEKOUEOMNJP-UHFFFAOYSA-N FC1=C(C=CC=C1Cl)C1(NC=CC(=N1)NCCCN(C)C)N Chemical compound FC1=C(C=CC=C1Cl)C1(NC=CC(=N1)NCCCN(C)C)N VQZLEKOUEOMNJP-UHFFFAOYSA-N 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000042846 PKC family Human genes 0.000 description 1
- 108091082203 PKC family Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102100024923 Protein kinase C beta type Human genes 0.000 description 1
- 101710094033 Protein kinase C beta type Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102100025234 Receptor of activated protein C kinase 1 Human genes 0.000 description 1
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 150000004074 biphenyls Chemical class 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000000555 contractile cell Anatomy 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013075 data extraction Methods 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- PTVWPYVOOKLBCG-ZDUSSCGKSA-N levodropropizine Chemical compound C1CN(C[C@H](O)CO)CCN1C1=CC=CC=C1 PTVWPYVOOKLBCG-ZDUSSCGKSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- ULDIVZQLPBUHAG-UHFFFAOYSA-N n',n',2,2-tetramethylpropane-1,3-diamine Chemical compound CN(C)CC(C)(C)CN ULDIVZQLPBUHAG-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- UZGLIIJVICEWHF-UHFFFAOYSA-N octogen Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 UZGLIIJVICEWHF-UHFFFAOYSA-N 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000019270 symptomatic heart failure Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81387506P | 2006-06-15 | 2006-06-15 | |
| US60/813,875 | 2006-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090023698A true KR20090023698A (ko) | 2009-03-05 |
Family
ID=38611102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097000880A Withdrawn KR20090023698A (ko) | 2006-06-15 | 2007-06-13 | 2-아닐리노-4-아미노알킬렌아미노피리미딘 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20070293525A1 (enExample) |
| EP (1) | EP2032543A1 (enExample) |
| JP (1) | JP5306190B2 (enExample) |
| KR (1) | KR20090023698A (enExample) |
| CN (1) | CN101506176A (enExample) |
| AR (1) | AR062822A1 (enExample) |
| AU (1) | AU2007257701A1 (enExample) |
| CA (1) | CA2655315A1 (enExample) |
| CL (1) | CL2007001748A1 (enExample) |
| IL (1) | IL195865A0 (enExample) |
| MX (1) | MX2008016007A (enExample) |
| RU (1) | RU2008152193A (enExample) |
| TW (1) | TW200815368A (enExample) |
| WO (1) | WO2007146977A1 (enExample) |
| ZA (1) | ZA200809945B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160030729A (ko) * | 2014-09-11 | 2016-03-21 | 한국화학연구원 | 폴리믹신 b 화합물을 포함하는 심혈관 질환의 예방 및 치료용 약학적 조성물 |
| KR101876514B1 (ko) * | 2016-11-08 | 2018-07-10 | 한국화학연구원 | 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007146981A2 (en) | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha |
| ES2610880T3 (es) | 2008-02-22 | 2017-05-03 | Rigel Pharmaceuticals, Inc. | Uso de 2,4-pirimidinadiaminas para el tratamiento de la aterosclerosis |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| WO2011075560A1 (en) * | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| MX2012014158A (es) | 2010-06-04 | 2013-02-07 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2). |
| ES2653967T3 (es) | 2010-11-10 | 2018-02-09 | Genentech, Inc. | Derivados de pirazol aminopirimidina como moduladores de LRRK2 |
| EP3313993A4 (en) | 2015-06-29 | 2019-06-19 | Regents of the University of Minnesota | ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE |
| CN109516959A (zh) * | 2018-12-03 | 2019-03-26 | 陕西师范大学 | 2-芳氨基-4-取代嘧啶类衍生物及其在制备抗肿瘤药物中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB592928A (en) | 1943-06-11 | 1947-10-03 | Francis Henry Swinden Curd | New pyrimidine compounds |
| US2437683A (en) * | 1948-03-16 | Pyrimedine compounds and method of | ||
| US2443305A (en) * | 1948-06-15 | Pyrimidine derivatives | ||
| DE833651C (de) | 1943-11-02 | 1952-03-10 | Ici Ltd | Verfahren zur Herstellung von neuen Pyrimidinabkoemmlingen |
| GB587550A (en) | 1944-09-25 | 1947-04-29 | Francis Henry Swinden Curd | New pyrimidine compounds |
| US3445467A (en) * | 1964-05-25 | 1969-05-20 | Ciba Geigy Corp | Biphenyl diphenylalkane and diphenylether compounds,amino - substituted on the phenyl rings |
| FR2244520B1 (enExample) | 1973-07-06 | 1977-02-04 | Ugine Kuhlmann | |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DK0945443T3 (da) | 1998-03-27 | 2003-06-02 | Janssen Pharmaceutica Nv | HIV-hæmmende pyrimidinderivater |
| EP0945442A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted pyrimidine derivatives |
| AU5438299A (en) * | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
| EE200100502A (et) | 1999-03-26 | 2002-12-16 | Astrazeneca Ab | Ühendid |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| IL159120A0 (en) * | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| WO2003026666A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
| WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
| ES2314106T3 (es) | 2001-10-17 | 2009-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion. |
| CA2463822A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
| SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| WO2004048343A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| AU2003288994A1 (en) * | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| WO2005003103A2 (en) | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
| US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| DK1663242T3 (da) | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| US20050209231A1 (en) * | 2004-01-16 | 2005-09-22 | Xu Wu | Compositions and methods for inducing cardiomyogenesis |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| WO2007146981A2 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha |
-
2007
- 2007-06-13 CN CNA2007800304560A patent/CN101506176A/zh active Pending
- 2007-06-13 JP JP2009515619A patent/JP5306190B2/ja not_active Expired - Fee Related
- 2007-06-13 AU AU2007257701A patent/AU2007257701A1/en not_active Abandoned
- 2007-06-13 MX MX2008016007A patent/MX2008016007A/es not_active Application Discontinuation
- 2007-06-13 KR KR1020097000880A patent/KR20090023698A/ko not_active Withdrawn
- 2007-06-13 EP EP07798479A patent/EP2032543A1/en not_active Withdrawn
- 2007-06-13 RU RU2008152193/04A patent/RU2008152193A/ru not_active Application Discontinuation
- 2007-06-13 CA CA002655315A patent/CA2655315A1/en not_active Abandoned
- 2007-06-13 US US11/762,406 patent/US20070293525A1/en not_active Abandoned
- 2007-06-13 WO PCT/US2007/071073 patent/WO2007146977A1/en not_active Ceased
- 2007-06-14 CL CL2007001748A patent/CL2007001748A1/es unknown
- 2007-06-14 TW TW096121543A patent/TW200815368A/zh unknown
- 2007-06-15 AR ARP070102630A patent/AR062822A1/es unknown
-
2008
- 2008-11-24 ZA ZA200809945A patent/ZA200809945B/xx unknown
- 2008-12-11 IL IL195865A patent/IL195865A0/en unknown
-
2009
- 2009-03-26 US US12/411,760 patent/US8158641B2/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160030729A (ko) * | 2014-09-11 | 2016-03-21 | 한국화학연구원 | 폴리믹신 b 화합물을 포함하는 심혈관 질환의 예방 및 치료용 약학적 조성물 |
| KR101876514B1 (ko) * | 2016-11-08 | 2018-07-10 | 한국화학연구원 | 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| AR062822A1 (es) | 2008-12-10 |
| US20070293525A1 (en) | 2007-12-20 |
| US8158641B2 (en) | 2012-04-17 |
| CN101506176A (zh) | 2009-08-12 |
| CA2655315A1 (en) | 2007-12-21 |
| MX2008016007A (es) | 2009-01-16 |
| WO2007146977A1 (en) | 2007-12-21 |
| TW200815368A (en) | 2008-04-01 |
| RU2008152193A (ru) | 2010-07-20 |
| IL195865A0 (en) | 2009-09-01 |
| AU2007257701A1 (en) | 2007-12-21 |
| EP2032543A1 (en) | 2009-03-11 |
| JP5306190B2 (ja) | 2013-10-02 |
| CL2007001748A1 (es) | 2008-01-25 |
| ZA200809945B (en) | 2009-07-29 |
| US20090181995A1 (en) | 2009-07-16 |
| JP2009540012A (ja) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20090023698A (ko) | 2-아닐리노-4-아미노알킬렌아미노피리미딘 | |
| US8354407B2 (en) | 2-anilino-4-(heterocyclic)amino-pyrimidines | |
| KR102304121B1 (ko) | 심장 상태에 대한 피리미딘디온 화합물 | |
| US9657013B2 (en) | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | |
| US6448271B1 (en) | Substituted benzimidazoles and their use as parp inhibitors | |
| US11197864B2 (en) | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | |
| US20070225308A1 (en) | 2-Amino Quinazoline Derivative | |
| KR102472103B1 (ko) | 국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체 | |
| EP3409668B1 (en) | Novel imidazole derivative having jnk inhibitory activity and use thereof | |
| EP3554504B1 (en) | Substituted pyrazole-pyrimidines, variants thereof, and uses thereof | |
| KR102114389B1 (ko) | 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| KR20230132191A (ko) | Grk5 억제용 화합물, 이의 제조방법 및 이를 유효성분으로 포함하는 grk5 활성 관련 질환의 예방 또는 치료용 약학 조성물 | |
| EA048949B1 (ru) | Соединения пиримидиндиона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20090115 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |